Drug Profile

Rebonuputemcel - DiscGenics

Alternative Names: IDCT; IDCT-001; Injectable discogenic cell therapy - DiscGenics

Latest Information Update: 23 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator DiscGenics
Class Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Intervertebral disc degeneration

Most Recent Events

03 Dec 2025 Phase-III clinical trials in Intervertebral disc degeneration in USA (Intraspinal) (NCT07254806)
09 Apr 2025 DiscGenics plans phase-III (DGX-A02 or PIVOT) trial for Intervertebral disc degeneration in USA in quarter two of 2025
16 Jul 2024 DiscGenics plans to file biologics license application (BLA) with US FDA in USA for Intervertebral disc degeneration

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com